An ongoing dialogue on HIV/AIDS, infectious diseases,
June 13th, 2011
More on Generic Antiretrovirals …
In the recent post on the approval of generic Combivir — and the lack of availability of generic Epivir (lamivudine, 3TC), which was both anticipated and likely to be more useful — I speculated there were several possible causes of this surprising turn of events.
But ultimately I concluded, “In sum, the real reason there’s no generic 3TC remains a mystery.”
Last week, however, I received a fascinating email from an industry representative, who has asked that I summarize the turn of events from their perspective:
- The Epivir patent in the US expired in May 2010.
- A generic company was granted exclusive rights to market a generic in the US for 6 months. (This is part of patent law.)
- The particular company that was granted exclusivity was not been able to manufacture a product that has met approvability standards by the FDA.
- During the period of exclusivity, furthermore, no other company can market a generic either — again, patent law in action.
Mystery solved — and thank you for the clarification.
But I hasten to add that this information was not widely known by HIV/ID specialists, and furthermore not easy to find. One of my colleagues has likened reading rulings on patent law for generics akin to learning English as a second language, a very apt analogy.
Categories: HIV, Infectious Diseases, Patient Care, Policy
Tags: 3tc, Combivir, Epivir, generic antiretrovirals, generics, HIV, lamivudine
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “More on Generic Antiretrovirals …”

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- The Paperwork Demands for Academic Medical Teaching Are OUT OF CONTROL
- Long-Acting Injectable HIV Therapy for People Who Won’t Take ART?
- More on Relapses after Paxlovid Treatment for COVID-19
- Mayo Clinic Study on Paxlovid Outcomes is Reassuring — but Likely Underestimates Rebound Rate
- Should We Prescribe Nirmatrelvir/r (Paxlovid) to Low-Risk COVID-19 Patients?
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
-
NEJM Journal Watch — Recent Infectious Disease Articles
- BNT162b2 Vaccine Effectiveness Against Omicron in Children Aged 5–11 Years
- Observations from ID and Beyond: Long-Acting Injectable HIV Therapy for People Who Won't Take ART?
- Benefits of Screening for Serum Cryptococcal Antigen in Patients with HIV-1 Infection
- Next-Generation Monoclonal Antibodies: Another Promising Approach to Malaria Prevention
- Cause of Recent Pediatric Acute Hepatitis Cases Remains Elusive
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff COVID-19 CROI cure darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
A great way to be introduced to patent law for generics and the sordid strategies used by pharmaceutical industry is through the reading of “The Truth About the Drug Companies” by Marcia Angell.